Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tanespimycin

A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:KOS-953
Abbreviation:17-AAG
Chemical structure:17-allyl-aminogeldanamycin
17-allylamino-17-demethoxy-geldanamycin
17-demethoxy-17-(2-propenylamino)geldanamycin
IND number:57966
NSC code:330507
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search